XML 45 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies Narrative (Details) (USD $)
Share data in Millions, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Segment
Dec. 31, 2013
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Restricted cash pledged as collateral $ 37,000us-gaap_CashCollateralForBorrowedSecurities $ 37,000us-gaap_CashCollateralForBorrowedSecurities
Property and equipment 279,000us-gaap_PropertyPlantAndEquipmentGross 38,000us-gaap_PropertyPlantAndEquipmentGross
Depreciation expense 17,000us-gaap_Depreciation 5,000us-gaap_Depreciation
Potentially dilutive securities excluded from calculation of diluted net loss per share 13.1us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount 8.2us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Comprehensive income 21,300,000us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest 17,900,000us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
Number of segments 1us-gaap_NumberOfOperatingSegments  
Clinical Trials [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Prepaid expenses $ 1,528,000us-gaap_PrepaidExpenseCurrentAndNoncurrent
/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis
= ljpc_ClinicalTrialsMember